Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $47.50.
EBS has been the topic of a number of analyst reports. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday, May 7th. Chardan Capital reduced their price objective on Emergent BioSolutions from $75.00 to $65.00 in a research note on Friday, April 29th. Wells Fargo & Company cut their target price on shares of Emergent BioSolutions from $46.00 to $38.00 in a research report on Wednesday, May 4th. Cantor Fitzgerald cut Emergent BioSolutions from an “overweight” rating to a “neutral” rating in a research report on Friday, April 29th. Finally, Cowen decreased their price target on shares of Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th.
In related news, Director Kathryn C. Zoon sold 1,996 shares of the stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $35.53, for a total value of $70,917.88. Following the completion of the transaction, the director now owns 12,381 shares of the company’s stock, valued at approximately $439,896.93. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.40% of the stock is owned by corporate insiders.
Shares of EBS stock opened at $32.19 on Friday. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 11.06 and a beta of 0.98. The company has a current ratio of 4.42, a quick ratio of 2.81 and a debt-to-equity ratio of 0.51. Emergent BioSolutions has a twelve month low of $27.61 and a twelve month high of $68.03. The company’s 50-day moving average price is $37.45 and its 200-day moving average price is $41.35.
Emergent BioSolutions (NYSE:EBS – Get Rating) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.06). Emergent BioSolutions had a net margin of 8.96% and a return on equity of 16.05%. The company had revenue of $307.50 million during the quarter, compared to analyst estimates of $282.54 million. During the same quarter last year, the business posted $1.53 EPS. Emergent BioSolutions’s quarterly revenue was down 10.3% compared to the same quarter last year. As a group, equities research analysts predict that Emergent BioSolutions will post 1.02 EPS for the current year.
About Emergent BioSolutions (Get Rating)
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- Get a free copy of the StockNews.com research report on Emergent BioSolutions (EBS)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.